Home › Leukemia › Connecticut › Hartford
Leukemia clinical trials in Hartford, CT
4 studies for Leukemia are looking for participants at sites in and around Hartford (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- Hartford HealthCare Cancer Institute, Hartford
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
RecruitingObservational study
- Connecticut Children's Medical Center, Hartford
Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester · 8 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Hartford
About Leukemia
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
More about Leukemia on MedlinePlus
Leukemia trials in other cities
- Houston, TX28 studies
- Boston, MA25 studies
- New York City, NY19 studies
- Los Angeles, CA16 studies
- Chicago, IL16 studies
- Durham, NC13 studies
- Baldwin Park, CA12 studies
- Nashville, TN12 studies
- Columbus, OH12 studies
- Philadelphia, PA12 studies
- Milwaukee, WI11 studies
- Atlanta, GA11 studies
Other studies in Hartford
- Non-Small Cell Lung Cancer12 studies
- Lung Cancer11 studies
- Major Depressive Disorder9 studies
- Cancer (all types)9 studies
- Breast Cancer9 studies
- Neuroblastoma8 studies
- Multiple Myeloma7 studies
- Pancreatic Cancer7 studies
- Prostate Cancer7 studies
- Ovarian Cancer7 studies
- Cardiovascular Disease7 studies
- Heart Failure7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.